Spectral markers in preneoplastic intestinal mucosa: An accurate predictor of tumor risk in the MIN mouse

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 7, 2005, Pages 1639-1645

  Roy, Hemant K ^a,c   Kim, Young L ^b   Wali, Ramesh K ^a   Liu, Yang ^b   Koetsier, Jennifer ^a   Kunte, Dhananjay P ^a   Goldberg, Michael J ^a   Backman, Vadim ^b  

^a Evanston Northwestern Healthcare ^*  (United States)

^b Northwestern University   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CELECOXIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RISK; CANCER SCREENING; COLON CARCINOGENESIS; CONTROLLED STUDY; CYTOARCHITECTURE; DIAGNOSTIC ACCURACY; DNA FINGERPRINTING; EARLY DIAGNOSIS; ELASTIC LIGHT SCATTERING FINGERPRINTING; GENETIC PREDISPOSITION; INTESTINE MUCOSA; LIGHT SCATTERING; MASS SCREENING; MOUSE; NONHUMAN; PRECANCER; PREDICTION; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; SPECTROSCOPY; WILD TYPE;

ANIMALS; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; PREDICTIVE VALUE OF TESTS; PYRAZOLES; SULFONAMIDES;

EID: 22244440496     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0837     Document Type: Article

References (40)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale. Update based on new evidence. Gastroenterology 2004;124:544-60.
3. Grady WM. Genetic testing for high-risk colon cancer patients. Gastroenterology 2003;124:1574-94.
4. Murff HJ, Spigel DR, Syngal S. Does this patient have a family history of cancer? An evidence-based analysis of the accuracy of family cancer history. JAMA 2004;292:1480-9.
5. Watson P, Ashwathnarayan R, Lynch HT, Roy HK. Tobacco use and increased colorectal cancer risk in patients with hereditary nonpolyposis colorectal cancer (Lynch syndrome). Arch Intern Med 2004;164:2429-31.
6. Mills SJ, Shepherd NA, Hall PA, Hastings A, Mathers JC, Gunn A. Proliferative compartment deregulation in the non-neoplastic colonic epithelium of familial adenomatous polyposis. Gut 1995;36:391-4.
7. Anti M, Marra G, Armelao F, et al. Rectal epithelial cell proliferation patterns as predictors of adenomatous colorectal polyp recurrence. Gut 1993;34:525-30.
8. Bernstein C, Bernstein H, Garewal H, et al. A bile acid-induced apoptosis assay for colon cancer risk and associated quality control studies. Cancer Res 1999;59:2353-7.
9. Chen LC, Hao CY, Chiu YS, et al. Alteration of gene expression in normal-appearing colon mucosa of APCmin mice and human cancer patients. Cancer Res 2004;64:3694-700.
10. Weyn B, Jacob W, da Silva VD, et al. Data representation and reduction for chromatin texture in nuclei from premalignant prostatic, esophageal, and colonic lesions. Cytometry 2000;41:133-8.
11. Backman V, Wallace MB, Perelman LT, et al. Detection of preinvasive cancer cells. Nature 2000;406:35-6.
12. Gurjar RS, Backman V, Perelman LT, et al. Imaging human epithelial properties with polarized light-scattering spectroscopy. Nat Med 2001;7: 1245-8.
13. Kim Y, Liu Y, Wali R, et al. Simultaneous measurement of angular, spectral, and azimuthal dependence of light scattering for characterization of tissue microarchitecture and its alteration in early precancer. IEEE J Select Top Quant Elect 2003;9:243-57.
14. Roy HK, Liu Y, Wali RK, et al. Four-dimensional elastic light-scattering fingerprints as preneoplastic markers in the rat model of colon carcinogenesis. Gastroenterology 2004;126:1071-81.
15. Wall RK, Roy HK, Kim Y, et al. Increased microvascular blood content is an early event in colon carcinogenesis. Gut 2005;54:654-60.
16. Wax A, Yang C, Muller M, et al. In situ detection of neoplastic transformation and chemopreventive effects in rat esophagus epithelium using angle-resolved low-coherence interferometry. Cancer Res 2003;63: 3556-9.
17. Roy HK, Karolski WJ, Ratashak A. Distal bowel selectivity in the chemoprevention of experimental colon carcinogenesis by the non-steroidal anti-inflammatory drug nabumetone. Int J Cancer 2001;92:609-15.
18. Roy HK, Karoski WJ, Ratashak A, Smyrk TC. Chemoprevention of intestinal tumorigenesis by nabumetone: induction of apoptosis and Bcl-2 down-regulation. Br J Cancer 2001;84:1412-6.
19. Hoglund M, Gisselsson D, Sail T, Mitelman F. Coping with complexity. emultivariate analysis of tumor karyotypes. Cancer Genet Cytogenet 2002; 135:103-9.
20. Mori Y, Selaru FM, Sato F, et al. The impact of microsatellite instability on the molecular phenotype of colorectal tumors. Cancer Res 2003;63: 4577-82.
21. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000;60:5040-4.
22. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM. Ape deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 2004; 279:43261-72.
23. Russello SV, Shore SK. SRC in human carcinogenesis. Front Biosci 2004;9: 139-44.
24. Mahmoud NN, Bilinski RT, Churchill MR, Edelmann W, Kucherlapati R, Bertagnolli MM. Genotype-phenotype correlation in murine Ape mutation: differences in enterocyte migration and response to sulindac. Cancer Res 1999;59:353-9.
25. Moran AE, Carothers AM, Weyant MJ, Redston M, Bertagnolli MM. Carnosol inhibits β-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J/Min/+ (Min/+) mouse. Cancer Res 2005;65: 1097-104.
26. Giardiello FM, Hamilton SR, Hylind LM, Yang VW, Tamez P, Casero RA Jr. Ornithine decarboxylase and polyamines in familial adenomatous polyposis. Cancer Res 1997;57:199-201.
27. Lynch HT, Schuelke GS, Kimberling WJ, et al. Hereditary nonpolyposis colorectal cancer (Lynch syndromes I and II). II. Biomarker studies. Cancer 1985;56:939-51.
28. Sams JS, Lynch HT, Burt RW, Lanspa SJ, Boland CR. Abnormalities of lectin histochemistry in familial polyposis coli and hereditary nonpolyposis colorectal cancer. Cancer 1990;66:502-8.
29. Gerdes H, Gillin JS, Zimbalist E, Urmacher C, Lipkin M, Winawer SJ. Expansion of the epithelial cell proliferative compartment and frequency of adenomatous polyps in the colon correlate with the strength of family history of colorectal cancer. Cancer Res 1993;53:279-82.
30. Cruz-Correa M, Cui H, Giardiello FM, et al. Loss of imprinting of insulin growth factor II gene: a potential heritable biomarker for colon neoplasia predisposition. Gastroenterology 2004;126:964-70.
31. Takayama T, Katsuki S, Takahashi Y, et al. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-84.
32. Sahu RK, Argov S, Bernshtain E, et al. Detection of abnormal proliferation in histologically "normal" colonic biopsies using FTIR-microspectroscopy. Scand J Gastroenterol 2004;39:557-66.
33. Edelstein PS, Thompson SM, Davies RJ. Altered intracellular calcium regulation in human colorectal cancers and in "normal" adjacent mucosa. Cancer Res 1991;51:4492-4.
34. Issa JP, Vertino PM, Wu J, et al. Increased cytosine DNA- methyltransferase activity during colon cancer progression. J Natl Cancer Inst 1993;85:1235-40.
35. Odin E, Wettergren Y, Nilsson S, et al. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clin Cancer Res 2003;9:6012-9.
36. Cross SS. Fractals in pathology. J Pathol 1997;182:1-8.
37. Waliszewski P, Molski M, Konarski J. On the holistic approach in cellular and cancer biology: nonlinearity, complexity, and quasi-determinism of the dynamic cellular network. J Surg Oncol 1998;68:70-8.
38. Horwitz J, Cohen E, Goldberg M, et al. Micro-architectural alterations in endoscopically-normal mucosa provides accurate risk stratification for colorectal neoplasia. Am J Gastroenterol 2004;99:A11.
39. Kettunen HL, Ketrunen AS, Rautonen NE. Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer Res 2003; 63:5136-42.
40. Roy HK, Iversen P, Hart J, et al. Down-regulation of SNAIL suppresses MIN mouse tumorigenesis: modulation of apoptosis, proliferation, and fractal dimension. Mol Cancer Ther 2004;3:1159-65.